MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PGNY had -$48,121K decrease in cash & cash equivalents over the period. $191,782K in free cash flow.

Cash Flow Overview

Change in Cash
-$48,121K
Free Cash flow
$191,782K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Sale of marketable securities
    • Stock-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Purchase of marketable securitie...
    • Repurchase of common stock
    • Purchase of property and equipme...
    • Others

Cash Flow
2025-12-31
Net income
58,520
Deferred tax (benefit) expense
-8,115
Non-cash interest expense (income)
434
Depreciation and amortization
4,948
Loss on disposal of property and equipment
-79
Stock-based compensation expense
131,867
Bad debt expense
20,526
Net accretion of discounts on marketable securities
866
Foreign currency exchange rate loss
0
Accounts receivable
5,117
Prepaid expenses and other current assets
11,947
Accounts payable
28,752
Accrued expenses and other current liabilities
417
Other noncurrent assets and liabilities
9,306
Net cash provided by operating activities
210,192
Purchase of property and equipment, net
18,410
Purchase of marketable securities
354,964
Sale of marketable securities
223,701
Acquisition of business, net of cash acquired
9,340
Net cash (used in) provided by investing activities
-159,013
Repurchase of common stock
81,657
Proceeds from exercise of stock options
86
Issuance costs on credit facility
3,087
Payment of employee taxes related to equity awards
15,848
Proceeds from contributions to employee stock purchase plan
1,144
Net cash used in financing activities
-99,362
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
62
Net (decrease) increase in cash, cash equivalents, and restricted cash
-48,121
Cash, cash equivalents, and restricted cash, beginning of year
162,314
Cash, cash equivalents, and restricted cash, end of year
114,193
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Stock-based compensationexpense$131,867K Net income$58,520K Accounts payable$28,752K Bad debt expense$20,526K Depreciation andamortization$4,948K Non-cash interestexpense (income)$434K Accrued expenses andother current...$417K Loss on disposal ofproperty and equipment-$79K Net cash provided byoperating activities$210,192K Effect of exchange ratechanges on cash, cash...$62K Canceled cashflow$35,351K Net (decrease)increase in cash, cash...-$48,121K Canceled cashflow$210,254K Sale of marketablesecurities$223,701K Proceeds fromcontributions to employee...$1,144K Proceeds from exercise ofstock options$86K Prepaid expenses andother current assets$11,947K Other noncurrentassets and liabilities$9,306K Deferred tax (benefit)expense-$8,115K Accounts receivable$5,117K Net accretion ofdiscounts on marketable...$866K Net cash (used in)provided by investing...-$159,013K Canceled cashflow$223,701K Net cash used infinancing activities-$99,362K Canceled cashflow$1,230K Purchase of marketablesecurities$354,964K Purchase of property andequipment, net$18,410K Acquisition of business, netof cash acquired$9,340K Repurchase of common stock$81,657K Payment of employeetaxes related to...$15,848K Issuance costs on creditfacility$3,087K

Progyny, Inc. (PGNY)

Progyny, Inc. (PGNY)